ReviewCancer medicine2014
A role for G-CSF and GM-CSF in nonmyeloid cancers.
Review in Cancer medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 114 citations in OpenAlex.
- Mitigating the prevalence and function of myeloid-derived suppressor cells by redirecting myeloid differentiation using a novel immune modulator.Journal for immunotherapy of cancer · 2022Trial
- Observational
- Understanding the dual role of granulocyte-macrophage colony-stimulating factor in the lung cancer tumor microenvironment and its therapeutic implications.Translational lung cancer research · 2026Review
- Case Report: Tyrosine kinase inhibitors in ROS1-rearranged and granulocyte colony-stimulating factor-producing lung squamous cell carcinoma.Frontiers in oncology · 2026Article
- Tuning of G-CSFR signaling by de novo-designed agonists.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Granulocyte colony-stimulating factor-producing cutaneous squamous cell carcinoma: A case report and literature review.Medicine · 2025Review
- Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.Immunity, inflammation and disease · 2025Review
- Serum Protein Profiling as theranostic biomarkers for Left- and Right-Sided Colon Cancer using LuminexCancer biomarkers : section A of Disease markers · 2025Article
- m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.Journal of translational medicine · 2025Review
- Causal relationship between inflammatory factors and gynecological cancer: a Bayesian Mendelian randomization study.Scientific reports · 2024Article
- Effect of colony‑stimulating factor in the mechanism of bone metastasis development (Review).Oncology reports · 2024Review
- Senescent cells promote breast cancer cells motility by secreting GM-CSF and bFGF that activate the JNK signaling pathway.Cell communication and signaling : CCS · 2024Article
- Article
- Expression of cytokines in pleural effusions and corresponding cell lines of small cell lung cancer.Translational lung cancer research · 2024Article
- CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.Central-European journal of immunology · 2024Article
- Boron in wound healing: a comprehensive investigation of its diverse mechanisms.Frontiers in bioengineering and biotechnology · 2024Review
- Chitosan-Based Dressing as a Sustained Delivery System for Bioactive Cytokines.International journal of molecular sciences · 2023Article
- Repurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors.Cancer biology & medicine · 2023Review
- A new strategy for treating colorectal cancer: Regulating the influence of intestinal flora and oncolytic virus on interferon.Molecular therapy oncolytics · 2023Review
- G-CSF Is a Novel Mediator of T-Cell Suppression and an Immunotherapeutic Target for Women with Colon Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) modulate progression of certain solid tumors. The G-CSF- or GM-CSF-secreting cancers, albeit not very common are, however, among the most rapidly advancing ones due to a cytokine-mediated immune suppression and angiogenesis. Similarly, de novo angiogenesis and vasculogenesis may complicate adjuvant use of recombinant G-CSF or GM-CSF thus possibly contributing to a cancer relapse. Rapid diagnostic tools to differentiate G-CSF- or GM-CSF-secreting cancers are not well developed therefore hindering efforts to individualize treatments for these patients. Given an increasing utilization of adjuvant G-/GM-CSF in cancer therapy, we aimed to summarize recent studies exploring their roles in pathophysiology of solid tumors and to provide insights into some complexities of their therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.